Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C.

Lung Cancer. 2019 Jan;127:96-102. doi: 10.1016/j.lungcan.2018.11.037. Epub 2018 Nov 27.

PMID:
30642559
2.

[Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].

Gaultier De Saint Basile H, Poisson C, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Tartour E, De Guillebon E.

Bull Cancer. 2018 Dec;105(12):1202-1208. doi: 10.1016/j.bulcan.2018.10.004. Epub 2018 Nov 22. French.

PMID:
30471959
3.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M.

Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. Review. French.

PMID:
30343945
4.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.

Reis R, Labat L, Allard M, Boudou-Rouquette P, Chapron J, Bellesoeur A, Thomas-Schoemann A, Arrondeau J, Giraud F, Alexandre J, Vidal M, Goldwasser F, Blanchet B.

J Pharm Biomed Anal. 2018 Sep 5;158:174-183. doi: 10.1016/j.jpba.2018.05.052. Epub 2018 Jun 1.

PMID:
29883880
5.

Nivolumab combined with ruxolitinib: antagonism or synergy?

Debureaux PE, Arrondeau J, Bouscary D, Goldwasser F.

Ann Oncol. 2018 May 1;29(5):1334-1335. doi: 10.1093/annonc/mdy077. No abstract available.

PMID:
29788168
6.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.

PMID:
29764856
7.

Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.

Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, Halpin R, Creasy T, Bantsimba-Malanda C, Arrondeau J, Goldwasser F, Boudou-Rouquette P, Fournel L, Roche N, Burgel PR, Goc J, Devi-Marulkar P, Germain C, Dieu-Nosjean MC, Cremer I, Herbst R, Damotte D.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940. doi: 10.1164/rccm.201706-1110OC.

PMID:
29518341
8.

Hepatic metastasis from basal cell carcinoma: A rare location with an unreported presentation.

Dohan A, Arrondeau J, Kramkimel N, Terris B, Barral M, Soyer P, Gaujoux S.

Diagn Interv Imaging. 2018 Jul - Aug;99(7-8):513-514. doi: 10.1016/j.diii.2018.01.016. Epub 2018 Feb 21. No abstract available.

PMID:
29475776
9.

Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S.

Invest New Drugs. 2017 Aug;35(4):537. doi: 10.1007/s10637-017-0475-7. No abstract available.

PMID:
28597150
10.

Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Franck N, Arrondeau J, Guégan S, Mansuet-Lupo A, Alexandre J, Damotte D, Avril MF, Dupin N, Aractingi S.

Invest New Drugs. 2017 Dec;35(6):842-847. doi: 10.1007/s10637-017-0476-6. Epub 2017 May 31.

PMID:
28569347
11.

Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.

Bretagne M, Jouinot A, Durand JP, Huillard O, Boudou Rouquette P, Tlemsani C, Arrondeau J, Sarfati G, Goldwasser F, Alexandre J.

Cancer Chemother Pharmacol. 2017 Jul;80(1):45-53. doi: 10.1007/s00280-017-3326-5. Epub 2017 May 15.

PMID:
28508095
12.

Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S.

Invest New Drugs. 2017 Aug;35(4):436-441. doi: 10.1007/s10637-017-0464-x. Epub 2017 Apr 10. Erratum in: Invest New Drugs. 2017 Jun 9;:.

PMID:
28396974
13.

Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients.

Puszkiel A, Noé G, Boudou-Rouquette P, Cossec CL, Arrondeau J, Giraud JS, Thomas-Schoemann A, Alexandre J, Vidal M, Goldwasser F, Blanchet B.

J Pharm Biomed Anal. 2017 May 30;139:30-36. doi: 10.1016/j.jpba.2017.02.041. Epub 2017 Feb 24.

PMID:
28260630
14.

Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.

Bigot F, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tlemsani C, Chapron J, Huillard O, Cessot A, Vidal M, Alexandre J, Blanchet B, Goldwasser F.

Invest New Drugs. 2017 Apr;35(2):242-246. doi: 10.1007/s10637-016-0400-5. Epub 2016 Oct 29.

PMID:
27796680
15.

Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.

Boudou-Rouquette P, Tlemsani C, Blanchet B, Huillard O, Jouinot A, Arrondeau J, Thomas-Schoemann A, Vidal M, Alexandre J, Goldwasser F.

Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1433-1444. Epub 2016 Aug 24. Review.

PMID:
27556889
16.

Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.

Lavaud P, Rousseau B, Ajgal Z, Arrondeau J, Huillard O, Alexandre J, Hulin A, Goldwasser F.

Breast Cancer Res Treat. 2016 May;157(1):191-2. doi: 10.1007/s10549-016-3798-8. Epub 2016 Apr 22. No abstract available.

PMID:
27106482
17.

[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].

Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, Goldwasser F.

Bull Cancer. 2016 Mar;103(3):259-72. doi: 10.1016/j.bulcan.2015.10.020. Epub 2016 Jan 29. Review. French.

PMID:
26832420
18.

Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision-Making.

Huillard O, Colombet I, Montheil V, Weiler F, Boudou-Rouquette P, Arrondeau J, Tlemsani C, Cessot A, Giroux J, Alexandre J, Goldwasser F, Vinant P.

Oncologist. 2015 Sep;20(9):e26. doi: 10.1634/theoncologist.2015-0131. Epub 2015 Aug 7. No abstract available.

19.

Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.

Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, Alexandre J, Goldwasser F.

Expert Opin Drug Metab Toxicol. 2015 May;11(5):785-94. doi: 10.1517/17425255.2015.1030392. Epub 2015 Mar 25. Review.

PMID:
25809423
20.

Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.

Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP, Alexandre J, Goldwasser F.

Expert Opin Investig Drugs. 2015 May;24(5):673-87. doi: 10.1517/13543784.2015.1005736. Epub 2015 Jan 20. Review.

PMID:
25599887
21.

Carcinoma of the salivary glands: guidelines and case report of sustained remission with docetaxel.

Arrondeau J, Le Nagat S, Lefèvre M, Tassart M, Touboul E, Lacau St Guily J, Huguet F.

J Clin Pharm Ther. 2015 Feb;40(1):116-8. doi: 10.1111/jcpt.12221. Epub 2014 Oct 10.

PMID:
25302593
22.

LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer.

Arrondeau J, Ammari S, Besse B, Soria JC.

J Thorac Oncol. 2014 Aug;9(8):e62-3. doi: 10.1097/JTO.0000000000000174. No abstract available.

23.

[Immunotherapies and targeted therapies in medical oncology].

Rousseau B, Champiat S, Loirat D, Arrondeau J, Lemoine N, Soria JC.

Bull Cancer. 2014 Jan 1;101(1):31-9. doi: 10.1684/bdc.2013.1865. Review. French.

PMID:
24333964
24.

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.

Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F.

Invest New Drugs. 2012 Oct;30(5):2046-9. doi: 10.1007/s10637-011-9764-8. Epub 2011 Oct 29.

PMID:
22038662
25.

Development of anti-cancer drugs.

Arrondeau J, Gan HK, Razak AR, Paoletti X, Le Tourneau C.

Discov Med. 2010 Oct;10(53):355-62. Review.

Supplemental Content

Loading ...
Support Center